Pavna Industries (PAVNAIND)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Strong sales growth of 35.99% in a competitive auto components market
• Profit growth of 328.57% and a low PEG ratio of 0.26 indicate positive momentum
• Healthy balance sheet: Debt/Equity of 0.37 and Piotroski F-Score of 7/9
• Promoter holding of 61.50% aligns ownership with minority investors

Concerns

• Weak capital efficiency: ROE of 4.61% and ROCE of 9.38%
• Rich valuation: P/E of 46.71 and P/B of 4.14 with zero dividend yield
• Latest quarterly net margin is thin at about 2.8% (₹3 Cr profit on ₹108 Cr sales)
• Triple-digit profit growth may be a low-base effect and may not be sustainable

AI Analysis

Let me look at Pavna Industries through my usual lens. At ₹20.91, the market is asking ₹288 Cr for this auto component business. A P/E of 46.71 is not what I call a bargain. Graham taught me to treat price as a quote; value must be anchored to earnings and assets. The company trades at 4.14 times book value, yet its book value is only ₹5.05 and its ROE is just 4.61%. In other words, the business is turning every rupee of equity into less than five paise of profit. Paying four times such equity is a demanding price. There are some positives. Sales are growing nearly 36%, and profit is up sharply at 328.57%, although from a thin base: the latest quarter produced sales of ₹108 Cr but only ₹3 Cr net profit, a roughly 2.8% margin. Debt is manageable at 0.37 times equity, and a Piotroski score of 7 suggests recent fundamentals are improving. Promoters own 61.5%, aligning their interests with mine. A zero dividend yield is acceptable if profits are reinvested well, but at these returns on capital, I wonder how much shareholder wealth is actually being created. The PEG ratio of 0.26 looks alluring only if triple-digit profit growth can continue. That is a big if in an auto components industry exposed to cyclical demand. I do not see a durable moat in these numbers. This is a fast grower trading on expectations, not a compounder selling below intrinsic value. If I owned it, I would watch whether sales growth converts into higher ROE and margins. If not, the high P/E will punish patient holders. I would prefer to wait for a margin of safety before paying up.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer